Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer.
Boost irradiation
Breast pain
Breast-conserving surgery
Radiation dermatitis
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
13 Oct 2020
13 Oct 2020
Historique:
received:
22
06
2020
accepted:
20
08
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
31
7
2021
Statut:
epublish
Résumé
Intensity-modulated radiotherapy (IMRT) improves dose homogeneity and late toxicity compared to simple tangential techniques in adjuvant whole-breast radiotherapy for patients with breast cancer. Simultaneous-integrated boost (SIB) radiotherapy shortens the overall treatment time and improves dose homogeneity. However, prospective randomized trials regarding IMRT with SIB for adjuvant radiotherapy in breast cancer are lacking. The IMRT-MC2 (MINT) trial is a phase III prospective randomized controlled trial comparing IMRT with SIB (Arm A: whole breast 28 × 1.8 Gy, Boost 28 × 2.3 Gy) to 3D-conformal radiotherapy with a sequential boost (Arm B: whole breast 28 × 1.8 Gy, boost 8 × 2 Gy) in patients with breast cancer after BCS. Indication for boost radiotherapy was defined as age < 70 years or age > 70 years with presence of additional risk factors. This is a retrospective analysis of acute toxicity at one of two trial sites. Five hundred two patients were randomized, of which 446 patients were eligible for this analysis. There was no statistically significant difference in terms of any grade radiation dermatitis between the two treatment arms at the end of treatment (p = 0.26). However, radiation dermatitis grade 2/3 (29.1% vs. 20.1 and 3.5% vs. 2.3%) occurred significantly more often in Arm A (p = 0.02). Breast/chest wall pain at the first follow-up visit was significantly more common in patients treated on Arm B (p = 0.02). Treatment on both arms was well tolerated, however there were some differences regarding radiodermatitis and breast pain. Further analyses are ongoing. clinicaltrials.gov , NCT01322854 , registered 24th March 2011.
Sections du résumé
BACKGROUND
BACKGROUND
Intensity-modulated radiotherapy (IMRT) improves dose homogeneity and late toxicity compared to simple tangential techniques in adjuvant whole-breast radiotherapy for patients with breast cancer. Simultaneous-integrated boost (SIB) radiotherapy shortens the overall treatment time and improves dose homogeneity. However, prospective randomized trials regarding IMRT with SIB for adjuvant radiotherapy in breast cancer are lacking.
METHODS
METHODS
The IMRT-MC2 (MINT) trial is a phase III prospective randomized controlled trial comparing IMRT with SIB (Arm A: whole breast 28 × 1.8 Gy, Boost 28 × 2.3 Gy) to 3D-conformal radiotherapy with a sequential boost (Arm B: whole breast 28 × 1.8 Gy, boost 8 × 2 Gy) in patients with breast cancer after BCS. Indication for boost radiotherapy was defined as age < 70 years or age > 70 years with presence of additional risk factors. This is a retrospective analysis of acute toxicity at one of two trial sites.
RESULTS
RESULTS
Five hundred two patients were randomized, of which 446 patients were eligible for this analysis. There was no statistically significant difference in terms of any grade radiation dermatitis between the two treatment arms at the end of treatment (p = 0.26). However, radiation dermatitis grade 2/3 (29.1% vs. 20.1 and 3.5% vs. 2.3%) occurred significantly more often in Arm A (p = 0.02). Breast/chest wall pain at the first follow-up visit was significantly more common in patients treated on Arm B (p = 0.02).
CONCLUSIONS
CONCLUSIONS
Treatment on both arms was well tolerated, however there were some differences regarding radiodermatitis and breast pain. Further analyses are ongoing.
TRIAL REGISTRATION
BACKGROUND
clinicaltrials.gov , NCT01322854 , registered 24th March 2011.
Identifiants
pubmed: 33050920
doi: 10.1186/s13014-020-01652-x
pii: 10.1186/s13014-020-01652-x
pmc: PMC7557053
doi:
Banques de données
ClinicalTrials.gov
['NCT01322854']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
235Subventions
Organisme : German Aerospace Center (DLR)/Federal Ministry of Education and Research (BMBF)
ID : 01ZP0504
Références
JAMA Oncol. 2015 Oct;1(7):931-41
pubmed: 26247543
Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):575-8
pubmed: 3972667
Lancet Oncol. 2006 Jun;7(6):467-71
pubmed: 16750496
Radiother Oncol. 2016 Dec;121(3):414-419
pubmed: 27637858
Radiat Oncol. 2018 Nov 7;13(1):218
pubmed: 30404664
Radiat Oncol. 2020 Jan 17;15(1):17
pubmed: 31952507
Radiother Oncol. 2009 Jul;92(1):34-41
pubmed: 19375808
BMC Cancer. 2011 Jun 15;11:249
pubmed: 21676232
Radiat Oncol. 2012 Jun 01;7:80
pubmed: 22656865
Phys Med Biol. 2007 Feb 21;52(4):1135-46
pubmed: 17264375
Radiat Oncol. 2019 Mar 7;14(1):39
pubmed: 30845971
Radiat Oncol. 2014 Jan 27;9:36
pubmed: 24467916
Breast. 2015 Oct;24(5):656-60
pubmed: 26371691
Radiother Oncol. 2013 Aug;108(2):269-72
pubmed: 24055289
Strahlenther Onkol. 2018 Jul;194(7):607-618
pubmed: 29383405
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):923-30
pubmed: 16904837
Cochrane Database Syst Rev. 2016 Jul 18;7:CD003860
pubmed: 27425588
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1087-95
pubmed: 25084611
J Clin Oncol. 2013 Dec 20;31(36):4488-95
pubmed: 24043742
Radiother Oncol. 2007 Mar;82(3):254-64
pubmed: 17224195
Breast Care (Basel). 2015 Oct;10(5):320-4
pubmed: 26688679
J Clin Oncol. 2018 Oct 31;:JCO1800317
pubmed: 30379626
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76
pubmed: 10524421
Strahlenther Onkol. 2020 Sep;196(9):764-770
pubmed: 32318767
Radiother Oncol. 2017 Jan;122(1):30-36
pubmed: 28062087
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e471-7
pubmed: 22494592
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059428
Strahlenther Onkol. 2018 Jun;194(6):520-532
pubmed: 29450591
Radiat Oncol. 2015 Jul 09;10:139
pubmed: 26156086
Int J Radiat Oncol Biol Phys. 1979 Feb;5(2):257-61
pubmed: 110740
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):567-573
pubmed: 30366007
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Sci Rep. 2019 Feb 26;9(1):2759
pubmed: 30808911
Biomed Res Int. 2014;2014:827475
pubmed: 25162031
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):523-30
pubmed: 19775834
Breast J. 2020 Oct;26(10):1946-1952
pubmed: 32648331
Radiol Med. 2019 Apr;124(4):309-314
pubmed: 30547358
J Clin Oncol. 2008 May 1;26(13):2085-92
pubmed: 18285602
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422